Form4insider filings, from the source

SEC Form 4 · accession 0001209191-16-092246

Kite Pharma, Inc. · KITE

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner
Rizwana F Sproule
Officer — VP Regulatory Affairs
Period of report
Jan 15, 2016
Accepted (ET)
Jan 19, 2016 · 8:23 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001510580

Table I — non-derivative securities

SecurityDateCodeSharesPriceA/DOwned afterD/INature of ownership
Common StockJan 15, 2016M6,800$1.35A15,541D
Common StockF2Jan 15, 2016S271$52.27D15,270D
Common StockF3Jan 15, 2016S645$53.89D14,625D
Common StockF4Jan 15, 2016S3,166$55.07D11,459D
Common StockF5Jan 15, 2016S1,918$55.60D9,541D
Common StockF6Jan 15, 2016S800$57.09D8,741D
Common StockJan 19, 2016M2,767$1.35A11,508D
Common StockF7Jan 19, 2016S497$53.55D11,011D
Common StockF8Jan 19, 2016S355$54.58D10,656D
Common StockF9Jan 19, 2016S635$55.67D10,021D
Common StockF10Jan 19, 2016S230$56.70D9,791D
Common StockF11Jan 19, 2016S852$57.74D8,939D
Common StockF12Jan 19, 2016S198$58.92D8,741D

Table II — derivative securities

SecurityConv. / exercise priceDateCodeSharesA/DExercisableExpiresUnderlyingUnderlying sharesOwned afterD/I
Employee Stock Option (Right to Buy)F13$1.35Jan 15, 2016M6,800D—Mar 24, 2024Common Stock6,800116,664D
Employee Stock Option (Right to Buy)F13$1.35Jan 19, 2016M2,767D—Mar 24, 2024Common Stock2,767113,897D

Explanation of responses